“One of the reasons we perform single-cell approaches is they allow us to pick up subtle differences that would be missed with more conventional tools,” says David S. Johnson, PhD, CEO and co-founder of GigaGen, a company that specializes in microfluidics and molecular genomics. Two GigaGen platforms, Surge and Magnify, can facilitate the development of polyclonal antibody therapies for transplant rejection, infectious diseases, and immunodeficiency disorders. The platforms can also help identify monoclonal antibody leads for checkpoint-resistant cancers.

Read the full story.